Abstract Library

#4599 Endosonography guided coloenterostomy for management of malignant small bowel ileus

Introduction: Small-bowel ileus (SBI) is often decisive for the prognosis in midgut neuroendocrine tumours (NET) and other peritoneally metastasised neoplasias. Conventional procedures of palliative care deliver unsatisfying results.

Conference:

Presenting Author: Weich A

Authors: Weich A, Retzbach L, Hartung V, Brand M, Kudlich T,

Keywords: Coloenterostomy, Endosonography, small bowel ileus, peritoneal carcinomatosis, midgut NET,

#4542 Results of active observation of pancreatic non-functioning neuroendocrine tumours – Medical registry data

Introduction: Algorithm for stage T1 pancreatic neuroendocrine tumours (PNETs) treatment requires clarification.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A, Petrova A,

Keywords: Neuroendocrine tumour, PNET, pancreatic NET, management, active observation, follow-up, registry, CHEK2, oestrogen,

#4518 Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602)

Introduction: Well-differentiated G3 NETs have been described as a distinct category recently, and randomised data regarding efficacy of therapy are scarce. In the phase 3 CABINET trial (NCT03375320), CABO significantly prolonged progression-free survival (PFS) compared with placebo (PB) in patients (pts) with advanced, previously treated, progressive well-differentiated extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades (Chan et al., NEJM, 2024).

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Zemla T, Geyer S, Pulsipher S, Behr S,

Keywords: cabozantinib, grade 3 neuroendocrine tumour, pancreatic neuroendocrine tumour, extra-pancreatic neuroendocrine tumour,

#4473 Somatostatin analogue delayed the recrudescence of stomach NET: A real-world study

Introduction: Type 1 gastric NENs (g-NENs) are common and relapse easily. Somstostatin analogues (SSAs) can inhibit gastrin secretion and cell proliferation. While the usage of SSAs in g-NENs is still controversial.

Conference:

Presenting Author: Cai W

Authors: Cai W, Zhang J, Ge W, Hu H,

Keywords: somatostatin analogue, Type 1 gastric NEN, real-world study,

#4425 Ampullary composite gangliocytoma/neuroma and neuroendocrine tumour management

Introduction: Ampullary composite gangliocytoma/neuroma and neuroendocrine tumour (CoGNET), previously called ampullary gangliocytic paragangliomas (GP) are a rare entity, with only few reported cases in the literature.

Conference:

Presenting Author: Karam E

Authors: Karam E, Hollenbach M, Heise C, Abou Ali E, Gulla A,

Keywords: ampulla of Vater, gangliocytic paraganglioma, pancreaticoduodenectomy, transduodenal surgical ampullectomy, endoscopic papillectomy, composite gangliocytoma/neuroma neuroendocrine tumour, CoGNET,